Rallybio Corp
Develops therapies for severe and rare diseases in hematology and complement dysregulation.
RLYB | NDAQ
Overview
Corporate Details
- ISIN(s):
- US75120L1008
- LEI:
- Country:
- United States of America
- Address:
- 234 CHURCH STREET, 6510 NEW HAVEN
- Website:
- https://rallybio.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Rallybio Corp. is a clinical-stage biotechnology company dedicated to developing and commercializing life-transforming therapies for patients with severe and rare diseases. The company focuses on translating scientific breakthroughs into treatments for conditions with limited or no existing therapeutic options. Its development pipeline concentrates on areas such as complement dysregulation and hematology. A key program includes RLYB116, a C5 inhibitor with potential best-in-class properties for complement-mediated diseases. Rallybio's mission is to address scientifically complex and previously inaccessible therapeutic challenges to profoundly change patient outcomes.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Rallybio Corp filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Rallybio Corp
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Rallybio Corp via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
